These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 23963927

  • 1. BAP1 protein is a progression factor in malignant pleural mesothelioma.
    Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH.
    Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
    [Abstract] [Full Text] [Related]

  • 2. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M.
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [Abstract] [Full Text] [Related]

  • 3. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA, El-Din RS, Sabri NA, Abdel-Rahman CA, Bastawisy AE.
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M.
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [Abstract] [Full Text] [Related]

  • 5. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
    Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V.
    Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
    [Abstract] [Full Text] [Related]

  • 6. Germline BAP1 mutations predispose to malignant mesothelioma.
    Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M.
    Nat Genet; 2011 Aug 28; 43(10):1022-5. PubMed ID: 21874000
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
    Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E.
    Lung Cancer; 2015 Jan 28; 87(1):77-9. PubMed ID: 25468148
    [Abstract] [Full Text] [Related]

  • 8. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ, Hromas R.
    Cancer Chemother Pharmacol; 2017 Oct 28; 80(4):861-867. PubMed ID: 28756516
    [Abstract] [Full Text] [Related]

  • 9. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
    De Rienzo A, Chirieac LR, Hung YP, Severson DT, Freyaldenhoven S, Gustafson CE, Dao NT, Meyerovitz CV, Oster ME, Jensen RV, Yeap BY, Bueno R, Richards WG.
    J Pathol; 2021 Jan 28; 253(1):68-79. PubMed ID: 32944962
    [Abstract] [Full Text] [Related]

  • 10. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L, Duregon E, Vatrano S, Izzo S, Giorcelli J, Rondón-Lagos M, Ascoli V, Ruffini E, Ventura L, Volante M, Papotti M, Scagliotti GV.
    J Thorac Oncol; 2016 Nov 28; 11(11):2006-2017. PubMed ID: 27422796
    [Abstract] [Full Text] [Related]

  • 11. Malignant Mesothelioma and Its Non-Asbestos Causes.
    Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL.
    Arch Pathol Lab Med; 2018 Jun 28; 142(6):753-760. PubMed ID: 29480760
    [Abstract] [Full Text] [Related]

  • 12. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR.
    Cancer Res; 2016 Jan 15; 76(2):206-15. PubMed ID: 26719535
    [Abstract] [Full Text] [Related]

  • 13. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
    Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR.
    Cancer Res; 2014 Aug 15; 74(16):4388-97. PubMed ID: 24928783
    [Abstract] [Full Text] [Related]

  • 14. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, Sculco M, Mancuso G, Guarrera S, Righi L, Grosso F, Libener R, Pavesi M, Mariani N, Casadio C, Boldorini R, Mirabelli D, Pasini B, Magnani C, Matullo G, Dianzani I.
    Cancer Lett; 2017 Oct 01; 405():38-45. PubMed ID: 28687356
    [Abstract] [Full Text] [Related]

  • 15. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct 01; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 16. Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
    Kukuyan AM, Sementino E, Kadariya Y, Menges CW, Cheung M, Tan Y, Cai KQ, Slifker MJ, Peri S, Klein-Szanto AJ, Rauscher FJ, Testa JR.
    Cancer Res; 2019 Aug 15; 79(16):4113-4123. PubMed ID: 31151962
    [Abstract] [Full Text] [Related]

  • 17. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
    Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M.
    J Thorac Oncol; 2015 Apr 15; 10(4):565-76. PubMed ID: 25658628
    [Abstract] [Full Text] [Related]

  • 18. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA.
    Mod Pathol; 2017 Feb 15; 30(2):246-254. PubMed ID: 27813512
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
    Betti M, Aspesi A, Ferrante D, Sculco M, Righi L, Mirabelli D, Napoli F, Rondón-Lagos M, Casalone E, Vignolo Lutati F, Ogliara P, Bironzo P, Gironi CL, Savoia P, Maffè A, Ungari S, Grosso F, Libener R, Boldorini R, Valiante M, Pasini B, Matullo G, Scagliotti G, Magnani C, Dianzani I.
    Genes Chromosomes Cancer; 2018 Nov 15; 57(11):573-583. PubMed ID: 30338612
    [Abstract] [Full Text] [Related]

  • 20. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.
    Hum Pathol; 2017 Feb 15; 60():86-94. PubMed ID: 27771374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.